[1]
World Health Organization (2013). World Malaria Report. Geneva, Switzerland.
[2]
Clark, T. D., Greenhouse, B., NjamaMeya, D., Nzarubara, B., Maiteki-Sebuguzi, C., Staedke, S. G., Seto, E., Kamya, M. R., Rosenthal, P. J., Dorsey, G: (2008) Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J InfectDis198:393-400.
[3]
Kreuels, B., Kreuzberg, C., Kobbe, R., Ayim-Akonor, M., Apiah-Thompson, P., Thompson, B., Ehmen, C., Adjei, S., Langefeld, I., Adjei, O., May, J: (2010) Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth. Blood 115:4551-4558.
[4]
Gong, L., Maiteki-Sebuguzi, C., Rosenthal, P. J., Hubbard, A. E., Drakeley, C. J., Dorsey, G., Greenhouse, B: (2012) Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood 119:3808-3814.
[5]
Perlmann, P., Troye-Bloomberg, M., (2002). Malaria and the Immune system in Humans. Malaria Immunology. Chemical Immunology. Basel, Karger 80:229-242.
[6]
Beeson, J. G., Osier, F. H. A. (2008): Engwerda C R. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 24(12):578–584.
[7]
Doolan, D. L., Dobaño, C., Baird, J. K. (2009): Acquired immunity to malaria. Clin Microbiol Rev. 22(1):13–36.
[8]
Stanisie, D. I., Richards, J. S., McCallum, F. J. (2009) “Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitaemia and protection from symptomatic illness,” Infection and Immunity, vol. 77, no. 3, pp. 1165–1174.
[9]
Tangteerawatana, P., Krudsood, S., Chalermrut, K., Looareesuwan, S., Khusmith, S. (2001): Natural human IgG subclass antibodies to Plasmodium falciparum blood stage antigens and their relation to malaria resistance in an endemic area of Thailand Southeast. South-East Asian J Trop Med Public 32:247-254.
[10]
Garraud, O., Mahanty, S., Perraut, R. 2003. Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol 24:30.
[11]
Aucan, C., Traore, Y., Tall, F., Nacro, B., Traore-Leroux, T., Fumoux, F, Rihet, P. (2000). High Immunoglobulin G2 (IgG2) and low IgG 4 Levels are Associated with Human Resistance to Plasmodium falciparum Malaria. Infect Immun 68:1252-1258.
[12]
Joana, D., Fabian, H., Vincent, G., Jean-Francois, F., Jacques, R., Pierre-Andre, C., Dominique, M., Maryvonne, K., Constantin, F., Sylviane, P. (2012). High levels of IgE auto antibody to 14-3-3epsilon protein correlate with protection against severe Plasmodium falciparum malaria, the journal of infectious disease
[13]
Desowitz, R. S., Elm, J., Alpers, M. P (1993): Plasmodium falciparum–Specific immunoglobulin G (IgG), IgM and IgE antibodies inpaired maternal-cord sera from East Sepik Province, Papua New Guinea. Infect Immun 61:988-993.
[14]
Maeno, Y., Steketee, R., Nagatake, T., Tegoshi, T., Desowitz, R. S., Wirima, J. J., Aikawa, M. (1993): Immunoglobulin complex deposits in Plasmodium falciparum-infected placentas from Malawi and Papua New Guinea. Am J Trop Med Hyg 1993, 49:574-580.
[15]
Maeno, Y., Perlmann, P., Perlmann, H., Kusuhara, Y., Taniguchi, K., Nakabayashi, T., Win, K., Looarreesuwan, S., Aikawa, M. (2000): IgE Deposition in brain microvessels and on parasite erythrocytes from cerebral malaria patients. Am J Trop Med Hyg, 63: 128-132. Matters most, quantity or quality? Mem Inst Oswaldo Cruz. 87 Suppl3:229-234.
[16]
Desowitz, R. S., (1989). Plasmodium Specific Immunoglobulin E in Sera from an Area of Holo endemic Malaria. Trans R Soc Trop Med Hyg, 83:478-479.
[17]
Perlmann, H., Helmby, H., Hagstedt, M., Carlson, J., Larsson, P. H., Troye-Blomberg, M., Perlmann, P. (1994): IgE elevation and IgE anti-malarial antibodies in Plasmodium falciparum malaria: Association of high IgE levels with cerebral malaria. Clin Exp Immunol 97:284-292.
[18]
Duarte, J., Deshpande, P., Guiyedi, V., Mécheri, S., Fesel, C., Cazenave, P-A., Mishra, G. C., Kombila, M., Pied, S. (2007): Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status. Malar J 6:1-13.
[19]
Jayawardena, A. N., Janeway, C. A., Kemp, J. D. (1979): Experimental malaria in the CBA/Nmouse. J Immunol 123:2532-2539.
[20]
Branch, O. H., Udhayakumar, V., Hightower, A. W., Oloo, A. J., Hawley, W. A., Nahlen, B. L. Bloland, P. B., Kaslow, D. C., Lal, A. A., (1998). A Longitudinal Investigation of IgG and IgM Antibody Response to Merozoite specific Protein-119kDa Domain of Plasmodium falciparum in Pregnant Women and Infants: association with Febrile Illness, Parasitemia and Anemia. Am J Trop Med Hyg 58:211-219.
[21]
National Population Commission (NPC) (2006). Population and Housing Census, Population distribution by Sex, State, LGA, and Senatorial district, http://www.population.gov.ng.
[22]
Perignon, J. L., and P. Druilhe. (1994). Immune mechanisms underlying the premonition against Plasmodium falciparum malaria. Mem.Inst.Oswaldo Cruz 89(Suppl.2):51-53
[23]
Shi, Y. P., Sayed, U., Qari, S. H., Roberts, J. M., Udhayakumar, V., Oloo, A. J., Hawley, W. A., Kaslow, D. C., Nahlen, B. L., Lal, A. (1996). Natural immune response to the C-terminal 19-kilo Dalton domain of Plasmodium falciparum merozoite surface protein1. InfectImmun64:2716.
[24]
Egan, A. F., Morris, J., Barnish, H., Allen, S., Greenwood, B. M., Kaslow, D. C., Holder, A. A., Riley, E. M. (1996). Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDaC-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173:765.
[25]
Dodoo, D., T. G. Theander, J. A. L. Kurtzhals, et al. 1999. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with clinical protection from malaria. Infect. Immun.67:2131-2137
[26]
Soe, S., Theisen, M., Roussilhon, C., Aye, K. C., Druilhe, P. (2004). Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72:247.
[27]
Perlmann, P., Troye Blomberg, M. (2002). Malaria and the Immune System in Humans. Malaria Immunology (2nded.), vol80. (pp. 229-242).
[28]
Aribot, G. C., Rogier, J. L., Sarthou, J. F., Trape, A. T., Balde, P. D., Roussilhon, C. (1996). Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg 54:449.
[29]
Taylor, R. R., Allen, S. J., Greenwood, B. M., Riley, E. M. (1998). IgG 3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 58: 406.
[30]
Cavanagh, D. R., Elhassan, I. M., Roper, C., Robinson, V. J., Giha, H., Holder, A. A., HviidL., Theander, T G, Arnot, D. E., McBridge J. S., (1998). A Longitudinal study of Type-Specific Antibody Responses to Plasmodium falciparium Merozoite Surface Protein-1 in an Area of Unstable Malaria in Sudan. J Immunol 161:347-359.
[31]
Boutlis, C. S., Fagan, P. K., Gowda, D. C., Lagog, M., Mgone, C. S., Bockarie, M. J., Anstey, N. M. (2003). Immunoglobulin G (IgG) Responses to Plasmodium falciparum Glycosyl phosphatidyl inositols Are Short-Lived and Predominantly of the IgG3 Subclass J Infect Dis. 187(5):862-865.
[32]
Kinyanjui, S. M., Conway, D. J., Lanar, D. E., Marsh, K., (2007). IgG Antibody Responses to Plasmodium falciparum Merozoite Antigens in Kenyan Children have a Short Half-Life. Malaria Journal 6:82-89.
[33]
McCallum F. J., Persson, K. E., Sutherland, C. J., Mugyenyi, C. K., Fowkes, F. J., (2008) The Dynamics of Naturally Acquired Immunity to Plasmodium falciparum Infection PLoS Comput Biol›v.8(10).
